AzTrials
AzTrials

SmokingPROSPERNCT04271371

Preventing Relapse to Smoking Among Prisoners After Release

An observational study of Smoking and Smoking Reduction, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
What is being tested?
Not yet developed
How many people
40 participants
Where
1 siteUnited Kingdom
Study dates
8 Aug 2019to 30 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Male prisoner population

Who may be able to join

  • All participants are aged 18 or over (no upper age limit)
  • Are currently residing in one of the three study sites (HMPs Nottingham, Ranby and Sudbury)
  • Male (women will not be held at any of the study sites)
  • Have a provisional release date within the next 2 months.
  • Are capable of understanding and consenting to the study.
  • Remand and sentenced prisoners.
Show all 16Show fewer
  • Who report that they are a current smoker and/or a current smoker prior to entering prison (smoked up to 7 days before entering prison), and/or were in prison (and still on the same sentence) and a current smoker prior to the smoke-free prison policy.
  • 3. Reception prisoner cross-sectional
  • All participants are aged 18 or over (no upper age limit)
  • Are currently residing in the open prison study site (HMP Sudbury)
  • Male (women will not be held at any of the study sites)
  • Have been in the open prison more than two weeks but for less than 3 months.
  • Have been transferred from a closed prison.
  • Are capable of understanding and consenting to the study.
  • Sentenced prisoners.
  • Who report that they were a current smoker prior to entering prison (smoked up to 7 days before entering prison), and/or were in prison (and still on the same sentence) and a current smoker prior to the smoke-free prison policy.

Who cannot join

  • Present a serious risk of harm to the researchers, highlighted in PNOMIS records or by a member of staff.
  • Non-smokers.
  • Being deported post release.
  • Been in prison for less than four weeks.
  • 3. Reception prisoner cross-sectional
  • Present a serious risk of harm to the researchers, highlighted in PNOMIS records or by a member of staff.
  • Been in prison for less than 2 weeks.
  • Non-smokers.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • University of Nottingham, School of Medicine

    Nottingham, Please Select, NG5 1PB

Other trials in United Kingdom

About this study

Official title: Preventing Relapse to Smoking Among Prisoners After Release: Developing and Piloting a Complex Health Intervention

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Since the introduction of smoke-free polices across Her Majesty's Prison and Probation Service (HMPPS) in England and Wales, prisoners are now obliged to abstain from smoking while held in prison. This represents a unique opportunity to promote lifelong cessation in this highly disadvantaged and marginalised group. However, evidence suggests most prisoners intend to resume smoking as soon as possible after release. A systematic review of prison smoke-free polices worldwide concluded that there was a need for new research to identify effective strategies to reduce relapse in these individuals.

Read the detailed description

The primary objective of this study will be to develop and pilot test the feasibility and acceptability of an intervention to help prevent prisoners relapse to smoking after release. The study will work in accordance with the Medical Research Council (MRC) framework for developing and evaluating complex interventions. The Preventing Relapse tO Smoking among PrisonErs after Release (PROSPER) study consists of three key Phases:

  1. Document the support provided to manage nicotine addiction during imprisonment and in the periods immediately before and after release; establish the extent to which prisoners intentionally resume or unintentionally relapse to smoking after release; and obtain views on how relapse might be prevented.
  2. Drawing on current literature and findings from Phase 1, develop and design an prototype intervention to prevent smoking relapse after release.
  3. To pilot the designed prototype intervention and conduct a process evaluation to inform the development of further work in this area.

The research will be carried out in three prisons in the East Midlands. The main duties will include recruitment of participants (HMPPS staff members and prisoners), data collection, data analysis, assist with intervention development and refining related intervention materials/resources, co-facilitate Patient and Public Involvement (PPI) groups, contribute to the ethical application for the pilot intervention, and preparation of manuscripts for peer-review publication.

Being tested
Not yet developed
Keywords
Smoking, Smoking Reduction, Electronic Cigarette Use, Prison
Medical subject headings
Smoking, Smoking Reduction, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Not yet developedOther

    A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.

Study groups in NCT04271371
Study groupRoleWhat they receive
Prototype interventionTo be developed through Phase 1 and 2
Receives: Other: Not yet developed

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To develop and pilot test the feasibility and acceptability of an intervention to help prevent prisoners relapse to smoking after release.

    Smoking abstinence rates at 1 week, 1 month and 3 months post release, self-reported.

    Measured: 3 years

Secondary outcomes (18)
  1. To document prisoners smoking history to date and levels of nicotine addiction.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  2. To document the support provided to manage nicotine addiction during imprisonment and in the periods immediately before and after release.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  3. The impact of smoke-free prison policy on prisoners smoking behaviours.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  4. To establish the extent to which prisoners intentionally resume or unintentionally relapse to smoking after release (and does their intended behaviour pre-release predict post-release behaviour).

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  5. To establish the extent to which prisoners relapse to smoking after transfer to an open prison where smoking is permitted in designated areas.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  6. To obtain views on triggers to smoking after release (and transfer to an open prison) and how relapse might be prevented.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  7. For those prisoners who return to smoking after release, at what point do they resume smoking (in days).

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  8. After release do prisoners use cessation pharmacotherapy, electronic cigarettes or NHS SSS support, or any other means of preventing relapse.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  9. Record and examine other potential predictors (as outlined in the international literature) of relapse to smoking after release from smoke-free prisons, e.g other negative health behaviours.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  10. For those prisoners who do return to smoking after release, do they smoke less, the same or more as they previously smoked before entering prison/and or before the prison service went smoke-free.

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  11. Review of methods of recruitment in prison and community follow-up (to feed into future pilot intervention study).

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

    Measured: 1 year

  12. To develop, design, and refine an intervention to prevent smoking relapse after release with input from fellow academics, stakeholders and PPI groups.

    Phase 2 (Intervention development)

    Measured: 1 year

  13. To develop logic models to map the problem and the prototype intervention.

    Phase 2 (Intervention development)

    Measured: 1 year

  14. To assess any barriers and facilitators to the developed intervention.

    Phase 3 (Intervention pilot \& Intervention process evaluation)

    Measured: 1 year

  15. To explore any unintended consequences as a result of the intervention.

    Phase 3 (Intervention pilot \& Intervention process evaluation)

    Measured: 1 year

  16. To identify aspects of the intervention and delivery that could be improved.

    Phase 3 (Intervention pilot \& Intervention process evaluation)

    Measured: 1 year

  17. Explore smoking abstinence rates at 1 week, 1 month and 3 months post release, self-reported and CO validated.

    Phase 3 (Intervention pilot \& Intervention process evaluation)

    Measured: 1 year

  18. Explore impact of the intervention on self-reported health, housing, reconviction rates, use of illicit substances in prisoner's post- release.

    Phase 3 (Intervention pilot \& Intervention process evaluation)

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2020
  2. Study start8 Aug 2019
  3. Primary completion1 May 2023
  4. Study completion30 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04271371
Sponsor's protocol ID
254028
Acronym
PROSPER
Status last verified
Feb 2024
First submitted
6 Sep 2019
Last updated
28 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Smoking and Smoking Reduction, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To develop and pilot test the feasibility and acceptability of an intervention to help prevent prisoners relapse to smoking after release. (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in